Treats attention deficit hyperactivity disorder (ADHD). ANDA 209675, held by Novast Labs. Clonidine Hydrochloride.
As of Nov 16, 2026, ANDA 209675 (Clonidine Hydrochloride), held by Novast Labs, was first approved by FDA on Mar 5, 2019, with 1 approved supplement and 0 published complete response letters.
Clonidine hydrochloride extended-release tablets is a centrally acting alpha 2 -adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 5, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clonidine Hydrochloride0.1MG · tablet, extended release;oral | Clonidine Hydrochloride | Rx |
| Aug 14, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 5, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters